Editor's Correspondence |

Placebo-Controlled Trials Are Unethical in Clinical Hypertension Research

Scott D. Halpern, BS; Jason H. T. Karlawish, MD
Arch Intern Med. 2000;160(20):3167-3168. doi:.
Text Size: A A A
Published online


Preston et al1 confirm the substantial effects of placebo on both blood pressure and adverse-event reporting. However, there are at least 3 reasons to question their conclusion that these facts warrant the continued use of placebo controls in trials of antihypertensive therapies for stage 1 and stage 2 hypertension.

First, the much higher rate of patients exceeding the blood pressure safety limits in the placebo group1 is cause for concern. Though the rates of serious complications were similar during the year-long trial, this does not mean the longer-term consequences of such uncontrolled hypertension will be similarly benign. The long-term consequences of relatively short periods of uncontrolled hypertension have yet to be fully elucidated, but they are unlikely to be negligible. In recognition of this, the Food and Drug Administration has considered it safe to give patients with hypertension placebo for "4-8 weeks"2 or the "short term"3 in randomized controlled trials of antihypertensive agents, not for a full year as Preston et al did.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles

Users' Guides to the Medical Literature
Clinical Scenario

Users' Guides to the Medical Literature
Example 1: Diabetes and Target Blood Pressure